CellaVision AB (publ)
CLVSF
Other OTC13.49
USD
- -
- -
ISIN
SE0000683484
Return %
Stock
S&P500
1Y
-30.03
26.84
3Y
-23.00
77.03
5Y
-60.89
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Simon Ostergaard
- Full Time Employees
- 228
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Mobilvägen 12 Lund Sweden 223 62
- IPO Date
- Aug 20, 2013
- Website
- cellavision.com
- Similar Companies
- Business
- CellaVision AB (publ) specializes in digital solutions for blood and body fluid analysis within the healthcare sector, serving a global market spanning Sweden, across Europe, the Middle East, Africa, the Americas, and the Asia Pacific region. The company provides advanced diagnostic instruments, including the CellaVision DM1200 and DM9600 systems, which digitally capture cellular images from blood smears and body fluid samples to automate analysis. Additionally, their CellaVision DC-1 analyzer is designed to streamline blood cell differentials, particularly for smaller laboratories. The product portfolio extends to a comprehensive suite of software applications. This includes the CellaVision Peripheral Blood Application, which standardizes and simplifies the morphological assessment of peripheral blood smears, and the CellaVision Advanced RBC Application, enabling detailed red blood cell morphology examinations. For body fluid analysis, the CellaVision Body Fluid Application automates morphological review, while the CellaVision Remote Review Software facilitates off-site slide interpretation, overcoming geographical barriers. Further offerings comprise CellaVision Server Software for integrated workflows across multiple testing locations, CellaVision Dashboard for monitoring analyzer performance and reviewer metrics, and CellaVision Proficiency Software, a cloud-based platform for evaluating and enhancing staff competency in cell morphology. Educational resources are also available through CellaVision CellAtlas, featuring mini-lectures and an extensive cell image library, alongside CellaVision VET, which offers digital microscopy tools tailored for veterinary hematology. CellaVision enhances laboratory efficiency and diagnostic accuracy by developing instruments, reagents, and software, including solutions for smear making and staining. The company primarily targets hospitals and commercial laboratories of various sizes, supporting both human and animal sample analysis. The firm also focuses on innovation, dedicating a significant portion of its revenue to research and development, particularly in areas like artificial intelligence and Fourier Ptychographic Microscopy. Recent developments include strategic partnerships aimed at advancing hematology solutions, new product application launches, and ongoing clinical trials for expanded capabilities such as bone marrow analysis, expected to reach the market by early 2026. Established in 1994, CellaVision AB (publ) maintains its headquarters in Lund, Sweden.
CellaVision AB (publ) (CLVSF) Q4 2025 Earnings Call Transcript
CellaVision AB (publ) (CLVSF) Q3 2025 Earnings Call Transcript